Overview
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell, serving as a critical electron carrier in mitochondrial energy production and as an essential substrate for enzymes involved in DNA repair, epigenetic regulation, and cellular stress responses. NAD+ levels decline significantly with age—by approximately 50% between ages 40 and 60—and this decline is increasingly recognized as a driver of age-related metabolic dysfunction, neurodegeneration, and disease.
The scientific interest in NAD+ restoration has exploded since the discovery that the sirtuin family of enzymes (SIRT1-7), which regulate longevity, inflammation, and metabolic health, are entirely dependent on NAD+ as a substrate. The pioneering work of Dr. David Sinclair at Harvard Medical School and Dr. Shin-ichiro Imai at Washington University has established NAD+ decline as one of the hallmarks of aging and a promising therapeutic target.
Multiple approaches to NAD+ restoration are under investigation, including direct IV or subcutaneous NAD+ administration, oral supplementation with NAD+ precursors (NMN and NR), and inhibition of NAD+-consuming enzymes (CD38 inhibitors). Each approach has distinct pharmacokinetic profiles, bioavailability characteristics, and evidence bases that inform their relative merits.
This guide examines the biology of NAD+, the evidence supporting its restoration for anti-aging and therapeutic purposes, the comparative pharmacology of different NAD+ boosting strategies, and the safety considerations relevant to NAD+ supplementation.
Quick facts
- Mechanism
- Essential coenzyme for cellular energy, DNA repair, and sirtuin activation
- Primary use
- Anti-Aging & Cellular Energy
- Evidence
- strong
- FDA
- Not approved
- Route
- IV infusion, subcutaneous injection, oral (NMN/NR precursors), or intranasal
- Typical results
- Measurable NAD+ level increases within hours of IV infusion; sustained benefits with ongoing supplementation
Chemical information
NAD+ (C₂₁H₂₇N₇O₁₄P₂) is a metabolic compound with a molecular weight of 663.4 g/mol. Its structural characteristics underpin its biological activity in metabolic regulation and energy homeostasis.
How NAD+ works
NAD+ functions in two primary capacities: as an electron carrier in oxidative phosphorylation (the primary mitochondrial energy production pathway) and as a substrate for NAD+-consuming enzymes including sirtuins (SIRT1-7), poly-ADP-ribose polymerases (PARPs), and CD38/CD157 ectoenzymes. In its role as an electron carrier, NAD+ accepts electrons from metabolic substrates (NADH form) and transfers them to the electron transport chain, driving ATP synthesis.
The sirtuin enzymes are NAD+-dependent deacetylases and ADP-ribosyltransferases that regulate gene expression, DNA repair, mitochondrial biogenesis, and inflammatory signaling. SIRT1 deacetylates p53, FOXO transcription factors, and PGC-1α, promoting cellular stress resistance, autophagy, and mitochondrial function. SIRT3 resides in mitochondria where it activates key metabolic enzymes and enhances oxidative phosphorylation efficiency.
PARPs consume large quantities of NAD+ during DNA damage repair, creating a competitive dynamic with sirtuins. In aging tissues with accumulated DNA damage, PARP hyperactivation depletes NAD+ pools, leaving insufficient NAD+ for sirtuin-mediated protective signaling. This creates a vicious cycle of declining NAD+, impaired DNA repair, mitochondrial dysfunction, and accelerated aging that NAD+ restoration aims to interrupt.
CD38, a glycoprotein expressed on immune cells, is the primary NAD+-degrading enzyme and its expression increases dramatically with aging and inflammation. Research has shown that CD38 activity accounts for the majority of age-related NAD+ decline, making CD38 inhibition a promising complementary strategy to NAD+ supplementation.
- Sirtuin activation: Essential substrate for SIRT1-7 enzymes controlling longevity, metabolism, and DNA repair
- Mitochondrial energy: Electron carrier driving oxidative phosphorylation and ATP production
- DNA repair: Required by PARP enzymes for poly-ADP-ribosylation DNA damage response
- Epigenetic regulation: Modulates histone deacetylation patterns affecting gene expression
- Circadian rhythm: NAD+ oscillation regulates SIRT1-CLOCK/BMAL1 circadian clock function
- Immune modulation: Influences macrophage polarization and inflammatory cytokine production
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| IV NAD+ bioavailability | 100% | Direct systemic delivery; most rapid NAD+ elevation |
| IV infusion duration | 2–6 hours (250–750 mg) | Slow infusion required to minimize side effects |
| Oral NMN bioavailability | ~30% (estimated) | Absorbed in small intestine; converted to NAD+ in tissues |
| Oral NR bioavailability | ~25–30% | Converted to NMN then NAD+ via salvage pathway |
| NAD+ half-life | ~1–2 hours (plasma) | Rapid intracellular uptake and metabolism |
| Cellular effect duration | 12–24+ hours | Intracellular NAD+ elevation persists beyond plasma clearance |
Dosing & administration
NAD+ dosing varies by indication and individual factors. No FDA-approved dosing exists for this compound; protocols in the literature derive from limited clinical or preclinical data and practitioner experience.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Safety data for NAD+ is primarily derived from preclinical studies and limited human data. Long-term effects in humans remain incompletely characterized.
Common
- • Flushing and warmth during IV infusion
- • Nausea or GI discomfort (oral precursors)
- • Chest tightness during rapid IV infusion
- • Headache
- • Fatigue (paradoxical, usually during initial loading)
- • Insomnia if taken late in the day
Serious / potential risks
- • Rapid IV infusion can cause significant discomfort and rare cardiac arrhythmia
- • Theoretical concern about fueling NAD+-dependent pathways in cancer cells
- • Potential interaction with chemotherapy agents
- • High-dose NMN may affect methylation pathways
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| Chemotherapy agents | Cancer cells may utilize increased NAD+ for survival and DNA repair | Avoid during active cancer treatment; consult oncologist |
| Alcohol | Ethanol metabolism consumes NAD+, potentially negating supplementation | Minimize alcohol intake during NAD+ protocols |
| Niacin (vitamin B3) | Additive NAD+ precursor effects; may increase flushing | Adjust niacin dose if combining with NAD+ supplementation |
| Metformin | Both activate AMPK pathway; potentially synergistic for metabolic health | Generally considered safe to combine; monitor blood glucose |
| Resveratrol | Synergistic sirtuin activation when combined with NAD+ boosting | Commonly combined in anti-aging protocols |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research suppliers | Varies widely | Quality and purity vary significantly between sources |
| Compounding pharmacies | Prescription required | Higher quality assurance and purity testing |
The bottom line
NAD+ is a metabolic compound with research interest in cellular energy, longevity, dna repair, sirtuin activation. While preclinical evidence is encouraging, it remains investigational and is not FDA-approved. Any use should be under qualified medical supervision.
Best for
- • Researchers studying metabolic regulation and energy homeostasis
- • Individuals interested in cellular energy under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
MOTS-c
Mitochondrial-derived peptide that also enhances cellular energy metabolism
SS-31
Mitochondria-targeted peptide improving electron transport chain function
Humanin
Mitochondrial peptide with cytoprotective and anti-aging properties
Epitalon
Telomerase-activating peptide targeting another hallmark of aging
Frequently asked questions
References
- [1] Yoshino J, Baur JA, Imai SI.. NAD+ intermediates: The biology and therapeutic potential of NMN and NR. Cell Metab (2018). doi: 10.1016/j.cmet.2017.11.002 PMID: 29249689
- [2] Rajman L, Chwalek K, Sinclair DA.. Therapeutic potential of NAD-boosting molecules: The in vivo evidence. Cell Metab (2018). doi: 10.1016/j.cmet.2018.02.011 PMID: 29514064
- [3] Camacho-Pereira J, Tarragó MG, Chini CCS, et al.. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab (2016). doi: 10.1016/j.cmet.2016.05.006 PMID: 27304511
- [4] Imai SI, Guarente L.. It takes two to tango: NAD+ and sirtuins in aging/longevity control. NPJ Aging Mech Dis (2016). doi: 10.1038/npjamd.2016.17 PMID: 28721271
- [5] Liao B, Zhao Y, Wang D, et al.. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners. J Int Soc Sports Nutr (2022). doi: 10.1186/s12970-022-00471-z PMID: 35794560